The major hurdles and emerging opportunities of CAR T-cell therapy

Marta Palhas — Fri, 26 Feb 2021 14:08:25 +0000

Sara Ghorashian, PhD, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK, outlines the remaining challenges in the CAR T-cell therapy space. CAR-T therapy is a revolutionary treatment, but numerous obstacles must be overcome to unlock the full potential of CAR-T. Additionally, Dr Ghoashian highlights that the biological principles of these cells need to be better understood to find improved solutions to meet the patients’ needs. This interview took place during the 3rd European CAR T-cell Meeting.

The challenges of CAR T-cell therapy for pediatric B-ALL

Marta Palhas — Fri, 26 Feb 2021 14:08:21 +0000

Sara Ghorashian, PhD, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK, outlines the challenges associated with CAR T-cell therapy for pediatric B-cell acute lymphoblastic leukemia (ALL). Discovering the best treatment phasing with other immunotherapies, such as blinatumomab and inotuzumab, improving the toxicity profile, and CAR T-cell persistence are some of the remaining challenges. In addition, CD19 negative relapses are another challenge that needs to be tackled. Dr Ghorashian goes on to discuss strategies for dual CAR targeting, in particular CD19CAT and CD22 CAR T-cells. This interview took place during the 3rd European CAR T-cell Meeting.

Sara Ghorashian – VJRegenMed

The major hurdles and emerging opportunities of CAR T-cell therapy

The challenges of CAR T-cell therapy for pediatric B-ALL